Get to know our clinical trials
Phase 2b/3, adaptive, randomized, active-controlled clinical trial to evaluate the efficacy, safety, and tolerability of povetacicept versus a calcineurin inhibitor in the treatment of primary membranous nephropathy.
Status
In recruitment
headquarters
Pamplona
Technical Summary
- A PHASE 2B/3, ADAPTIVE, RANDOMIZED, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF POVETACICEPT VERSUS A CALCINEURIN INHIBITOR IN THE TREATMENT OF PRIMARY MEMBRANOUS NEPHROPATHY.
- Code EudraCT: 2025-521661-27-00
- Protocol number: VX24-AIS-D10
- Promoter: Vertex Pharmaceuticals
- Molecule/Drug: Povetacicept
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.